OTCMKTS:RGRX - RegeneRx Biopharmaceuticals Stock Price, News, & Analysis

$0.1850
+0.01 (+2.78 %)
(As of 06/26/2019 04:00 PM ET)
Today's Range
$0.1701
Now: $0.1850
$0.1850
50-Day Range
$0.1550
MA: $0.19
$0.21
52-Week Range
$0.07
Now: $0.1850
$0.35
Volume45,600 shs
Average Volume53,559 shs
Market Capitalization$24.33 million
P/E RatioN/A
Dividend YieldN/A
Beta0.68
RegeneRx Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4 (Tß4), for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RGRX
CUSIPN/A
Phone301-208-9191

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$70,000.00
Book Value($0.02) per share

Profitability

Net Income$-1,990,000.00
Net Margins-752.96%

Miscellaneous

Employees3
Market Cap$24.33 million
Next Earnings Date7/2/2019 (Estimated)
OptionableNot Optionable

Receive RGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RGRX and its competitors with MarketBeat's FREE daily newsletter.

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Frequently Asked Questions

What is RegeneRx Biopharmaceuticals' stock symbol?

RegeneRx Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "RGRX."

When is RegeneRx Biopharmaceuticals' next earnings date?

RegeneRx Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July 2nd 2019. View Earnings Estimates for RegeneRx Biopharmaceuticals.

Has RegeneRx Biopharmaceuticals been receiving favorable news coverage?

News stories about RGRX stock have trended positive on Wednesday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. RegeneRx Biopharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for RegeneRx Biopharmaceuticals.

Who are some of RegeneRx Biopharmaceuticals' key competitors?

What other stocks do shareholders of RegeneRx Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RegeneRx Biopharmaceuticals investors own include Biocept (BIOC), Rexahn Pharmaceuticals (REXN), Cytori Therapeutics (CYTX), Gemphire Therapeutics (GEMP), TrovaGene (TROV), Hemispherx BioPharma (HEB), Palatin Technologies (PTN), ACADIA Pharmaceuticals (ACAD), Celsion (CLSN) and Conatus Pharmaceuticals (CNAT).

Who are RegeneRx Biopharmaceuticals' key executives?

RegeneRx Biopharmaceuticals' management team includes the folowing people:
  • Dr. Allan L. Goldstein, Founder, Chairman, Chief Scientific Officer & Chairman of Scientific Advisor Board (Age 81)
  • Mr. J. J. Finkelstein, Pres, CEO & Director (Age 67)
  • Mr. Dane R. Saglio, Chief Financial Officer (Age 61)
  • Dr. Nabila A. Turjman Ph.D., Exec. Director of Regulatory Affairs

How do I buy shares of RegeneRx Biopharmaceuticals?

Shares of RGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is RegeneRx Biopharmaceuticals' stock price today?

One share of RGRX stock can currently be purchased for approximately $0.1850.

How big of a company is RegeneRx Biopharmaceuticals?

RegeneRx Biopharmaceuticals has a market capitalization of $24.33 million and generates $70,000.00 in revenue each year. RegeneRx Biopharmaceuticals employs 3 workers across the globe.View Additional Information About RegeneRx Biopharmaceuticals.

What is RegeneRx Biopharmaceuticals' official website?

The official website for RegeneRx Biopharmaceuticals is http://www.regenerx.com/.

How can I contact RegeneRx Biopharmaceuticals?

RegeneRx Biopharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 470, ROCKVILLE MD, 20850. The biopharmaceutical company can be reached via phone at 301-208-9191 or via email at [email protected]


MarketBeat Community Rating for RegeneRx Biopharmaceuticals (OTCMKTS RGRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  78 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  142
MarketBeat's community ratings are surveys of what our community members think about RegeneRx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe RGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel